Skip to main content
European Commission logo print header

The first simple monitoring device for Parkinson and other Tremor diseases

Periodic Reporting for period 1 - Tremipen (The first simple monitoring device for Parkinson and other Tremor diseases)

Reporting period: 2017-12-01 to 2018-03-31

Tremitas GmbH was founded in 2015 in Austria. We developed and patented Tremipen®, a medical device that allows Parkinson’s Disease (PD) and Essential Tremor (ET) patients to monitor their tremor at home. We are now developing Tremipen®Diff, a diagnostic system for the differential diagnosis between ET and PD. Currently no test exits that can definitively diagnose either ET or PD. The diagnosis relies on the subjective criteria of doctors that decide the diagnostic process based on a complete medical/symptom, family and medication history and examination. In contrast Tremipen®Diff is able to objectively and accurately diagnose these diseases, allowing their proper management and treatment. Tremipen®Diff technology is robust and accurate, fast and inexpensive compared to current methods.
We have performed a feasibility study focusing on 3 main areas. Technically, we have studied the developments needed for the technical finalization of Tremipen®Diff. We have also prepared an Execution Plan for the development of Tremipen®Diff, including planning, organization, risk analysis and budget. Commercially, we have assessed the existing and prospective markets, including the competition, to consolidate our marketing strategy. Moreover, we have performed a patent search to ensure our Freedom-to-Operate. Finally, we have done a 5-year financial forecast.
Tremipen®Diff will have a significant impact on: 1) ET and PD patients: It will improve their quality of life as they will be spared pain and uncertainty, psychological impact associated with misdiagnosis and suboptimal pharmacological management of their disease. 2) Physicians and neurologists: It will allow them to better and faster diagnose tremor disorders, avoiding misdiagnoses and leading to proper treatments. 3) Company: It will boost Tremitas’ growth 4) Healthcare system: It will decrease the cost of improper disease management and inefficient treatment of PD and ET, and alternative expensive diagnosis methods.